BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Linagliptin: Phase III data

In a double-blind Phase III trial in 227 Type II diabetics for whom metformin therapy is inappropriate, once-daily 5 mg oral linagliptin as monotherapy met the primary endpoint of significantly reducing HbA1c from baseline to week 18 vs. placebo (0.57% placebo-adjusted mean reduction, p<0.0001). Additionally, a significantly greater proportion of patients receiving linagliptin achieved a reduction in HbA1c to <7%, and a reduction in...

Read the full 300 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >